A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)

BACKGROUND: The anti‐interleukin 13 (IL‐13) monoclonal antibody lebrikizumab improves lung function in patients with moderate‐to‐severe uncontrolled asthma, but its effects on airway inflammation and remodelling are unknown. CLAVIER was designed to assess lebrikizumab's effect on eosinophilic i...

Descripción completa

Detalles Bibliográficos
Autores principales: Austin, Cary D., Gonzalez Edick, Melissa, Ferrando, Ronald E., Solon, Margaret, Baca, Miriam, Mesh, Kathryn, Bradding, Peter, Gauvreau, Gail M., Sumino, Kaharu, FitzGerald, J. Mark, Israel, Elliot, Bjermer, Lief, Bourdin, Arnaud, Arron, Joseph R., Choy, David F., Olsson, Julie K., Abreu, Francis, Howard, Monet, Wong, Kit, Cai, Fang, Peng, Kun, Putnam, Wendy S., Holweg, Cécile T.J., Matthews, John G., Kraft, Monica, Woodruff, Prescott G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756263/
https://www.ncbi.nlm.nih.gov/pubmed/32909660
http://dx.doi.org/10.1111/cea.13731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756263/
https://www.ncbi.nlm.nih.gov/pubmed/32909660
http://dx.doi.org/10.1111/cea.13731

Ejemplares similares